IVVD Invivyd, Inc.

BUSINESS SUMMARY

Invivyd is a monoclonal-antibody company focused on COVID-19 prevention and treatment in immunocompromised populations. The company's lead product Pemgarda (pemivibart) is FDA-authorized for pre-exposure prophylaxis (PrEP) of COVID-19 in adults who are unlikely to mount an adequate immune response from vaccination — primarily organ-transplant recipients, oncology patients on immunosuppressive therapy, and patients with primary immunodeficiencies.

Revenue is product sales of Pemgarda through specialty distribution channels to academic medical centers and large oncology and transplant clinics that manage immunocompromised populations.

MARKET OPPORTUNITY

The immunocompromised-COVID-PrEP market exists because for these patients, vaccination doesn't provide adequate protection. The population is real and persistent — every transplant patient, every patient on B-cell-depleting therapy, every patient with primary immunodeficiency is exposed to the same pandemic-residual COVID-circulation environment as everyone else, but without vaccination's protective benefit.

US addressable population is roughly 7-10 million immunocompromised individuals depending on definitional thresholds. Realistic capture rate is much smaller — Pemgarda requires IV infusion every 3 months, which limits adoption to motivated patients with infusion-center access.

Revenue growth of 110% YoY reflects the post-launch ramp from a small base. The headline rate flatters; the absolute revenue trajectory is the more relevant metric.

REVENUE QUALITY

The economics reflect a single-product specialty-biologic launch:

• Gross margin 92.9% — high, characteristic of specialty-biologic pricing
• Operating margin — improving but still pressured by sales-force-buildout costs
• Revenue $53M TTM — small absolute base
• P/S ~7.9 — premium reflecting single-product launch optimism plus pipeline-NPV

COMPETITIVE ADVANTAGE

Pemgarda is currently the only FDA-authorized COVID-19 PrEP option for immunocompromised patients in the US — predecessors AstraZeneca's Evusheld and Lilly's bebtelovimab were withdrawn as variants emerged that they couldn't neutralize. Invivyd's discovery platform is built around continuous antibody updating to track variant evolution, which is the structural advantage if SARS-CoV-2 keeps shifting.

That said, the moat depends entirely on continued variant-neutralization. If a variant emerges that Pemgarda doesn't cover, the product loses its PrEP authorization rapidly (precedent: Evusheld). The competitive landscape is therefore the variant-evolution landscape, not other companies.

GROWTH THESIS

The thesis is binary on two variables: (1) does SARS-CoV-2 continue circulating at levels that motivate immunocompromised patients to seek PrEP, and (2) does Pemgarda continue neutralizing dominant variants. If both hold, the patient population is real and the launch ramp continues. If either fails, the revenue base disappears quickly.

The pipeline includes variant-updated antibody candidates that would replace Pemgarda if needed — but each requires its own FDA authorization process, which is faster than de novo approval but not instant.

KEY RISKS

The variant-escape risk dominates. A SARS-CoV-2 variant that Pemgarda doesn't neutralize would force the product off-label in days; FDA authorization withdrawal would follow. Invivyd has variant-updated candidates in development specifically to manage this scenario, but the gap between Pemgarda losing efficacy and a successor being authorized is the binary commercial risk.

Secondary risk: COVID-19 circulation could decline to levels where PrEP becomes uneconomic. The current circulating-virus environment supports the commercial case; a meaningful prolonged decline (or vaccine improvements that close the immunocompromised-protection gap) compresses demand.

VERDICT

The 78.7/100 score captures the launch-revenue ramp and the high-margin biologic economics, but materially understates variant-escape binary risk. This is fundamentally a position that performs as long as SARS-CoV-2 keeps circulating and Pemgarda keeps neutralizing — both probabilistic, both outside management control.

For investors with conviction on long-term variant-residual COVID circulation and the immunocompromised-protection-gap remaining unsolved by vaccination, IVVD is the principal liquid pure-play. For investors uncomfortable with binary biotech outcomes, the thesis is too narrow.